Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net revenues
Total net revenues			$ 1,116	$ 814	$ 8,362
Cost of revenues
Total costs of revenues			634	616	3,723
Gross profit			482	198	4,639
Operating costs and expenses
Research and development		2,551	3,870	8,489	10,491
General and administrative		2,685	3,687	12,456	14,999
Sales and marketing			93		2,718
Restructuring and other charges			242	38	678
Impairment of assets held for sale		169		223
Total operating costs and expenses		5,405	7,892	21,206	28,886
Operating loss		(5,405)	(7,410)	(21,008)	(24,247)
Other income (expense), net
Gain on extinguishment of debt					3,612
Change in fair value of common stock warrant liability		1,984	6,354	13,719	4,134
Inducement loss on sale of liability classified warrants					(5,197)
Interest expense, net		(4)	(29)	(33)	(106)
Other income, net		25	64	83	185
Net loss and comprehensive loss		$ (3,400)	$ (1,021)	$ (7,239)	$ (21,619)
Net loss per share attributable to common stockholders
Basic*	[1]	$ (0.47)	$ (0.31)	$ (1.08)	$ (6.81)
Diluted*	[1]	$ (0.47)	$ (0.37)	$ (1.54)	$ (6.81)
Weighted average shares outstanding
Basic*	[1],[2]	7,215,898	3,251,387	6,724,876	3,174,697
Diluted*	[1]	7,215,898	3,270,188	7,505,128	3,176,787
Product [Member]
Net revenues
Total net revenues					$ 2,924
Cost of revenues
Total costs of revenues					448
Service [Member]
Net revenues
Total net revenues			1,116	814	5,438
Cost of revenues
Total costs of revenues			$ 634	$ 616	$ 3,275

[1] Giving retroactive effect to the 1-for-25 reverse stock split effectuated on May 16, 2022

[2] In December 2020, January 2021, and June 2022, the Company sold pre-funded warrants to purchase up to 209,522, 96,836, and 2,722,818 shares of common stock, respectively. The shares of common stock associated with the pre-funded warrants are considered outstanding for the purposes of computing earnings per share prior to exercise because the shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The pre-funded warrants sold in December 2020 and January 2021 were exercised in January 2021 and 488,659, 545,000, and 1,689,159 of the pre-funded warrants sold in June 2022 were exercised in June 2022, July 2022, and August 2022, respectively, and included in the denominator for the period of time the warrants were outstanding.